angiotensin
convert
enzym
dipeptidyl
carboxypeptidas
kininas
ii
ec
ace
play
major
role
metabol
mani
differ
peptid
includ
angiotensin
ang
bradykinin
kallidin
nacetylserylaspartyllysylprolin
acsdkp
ace
inhibitor
establish
therapi
heart
failur
ischaem
heart
diseas
alter
ang
ii
bradykinin
kallidin
acsdkp
peptid
level
implic
mechan
therapi
chapter
briefli
describ
renin
angiotensin
kallikrein
kinin
acsdkp
system
role
cardiovascular
physiolog
diseas
role
ace
inhibit
treatment
prevent
heart
failur
ischaem
heart
diseas
summaris
possibl
mechan
therapeut
benefit
ace
inhibitor
describ
exhaust
review
focus
aspect
relev
clinic
applic
ace
inhibitor
figur
show
outlin
pathway
ang
peptid
format
metabol
addit
classic
pathway
involv
renin
ace
altern
pathway
propos
campbel
remain
mani
question
concern
mechan
ang
peptid
format
discret
tissu
compart
heart
serin
proteas
exampl
may
form
ang
ii
process
independ
renin
site
inflamm
coagul
kallikrein
andor
cathepsin
g
may
activ
figur
pathway
ang
peptid
format
metabol
adapt
campbel
studi
nephrectomis
anim
show
main
mechan
ang
peptid
format
heart
involv
kidneyderiv
renin
campbel
et
al
danser
et
al
renin
messeng
rna
mrna
level
heart
low
undetect
de
mello
et
al
cardiac
renin
express
may
howev
induc
myocardi
infarct
macrophag
myofibroblast
may
express
renin
site
repair
sun
et
al
ang
peptid
deriv
angiotensinogen
although
angiotensinogen
may
produc
low
level
heart
dostal
et
al
paul
et
al
plasma
main
sourc
angiotensinogen
ang
peptid
format
heart
ace
membranebound
zinccontain
metallopeptidas
cleav
membran
releas
solubl
ace
found
plasma
fluid
erdo
ace
two
catalyt
domain
differenti
substrat
specif
suscept
ace
inhibitor
wei
et
al
wei
et
al
jaspard
et
al
tabl
list
mani
substrat
ace
ace
substrat
relat
cardiac
function
ang
bradykinin
kallidin
peptid
acsdkp
catalyt
domain
ace
poss
dipeptidyl
carboxypeptidas
endopeptidas
activ
cleav
ang
bradykinin
bradykinin
substanc
p
howev
ntermin
catalyt
domain
cleav
lutein
bradykinin
bradykinin
bradykinin
ly
bradykinin
kallidin
ly
bradykinin
ly
bradykinin
substanc
p
nacetylserylaspartyllysylprolin
acsdkp
chemotact
peptid
neurotensin
luteinis
hormonereleas
hormon
lhrh
enkephalin
cholecystokinin
gastrin
adapt
ehler
et
al
erdo
hooper
rieger
et
al
ise
hormonereleas
hormon
lhrh
acsdkp
effici
ctermin
domain
jaspard
et
al
rousseau
et
al
two
catalyt
domain
ace
interact
differ
ace
inhibitor
captopril
enalapril
lisinopril
trandolapril
highli
potent
inhibitor
domain
wherea
trandolapril
lisinopril
enalapril
show
prefer
ctermin
catalyt
domain
captopril
show
prefer
ntermin
catalyt
domain
wei
et
al
ace
widespread
tissu
distribut
includ
vascular
endothelium
smooth
muscl
cell
brush
border
proxim
tubul
cell
kidney
brain
erdo
ace
express
endothelium
coronari
vasculatur
endocardium
epicardium
valv
human
heart
dostal
et
al
ace
also
express
cardiac
fibroblast
fibroblast
express
ace
increas
border
zone
myocardi
infarct
dostal
et
al
burrel
et
al
cardiac
ace
express
upregul
heart
failur
hirsch
et
al
studer
et
al
mani
differ
cell
type
express
ang
receptor
heart
type
ang
receptor
express
coronari
smooth
muscl
endotheli
cell
cardiomyocyt
fibroblast
nerv
conduct
tissu
regitzzagrosek
et
al
receptor
express
fibroblast
endotheli
cell
regitzzagrosek
et
al
heart
failur
cardiomyocyt
receptor
express
may
downregul
wherea
fibroblast
express
receptor
increas
ohkubo
et
al
receptor
mediat
known
action
ang
ii
continu
uncertainti
role
receptor
may
mediat
action
ang
ii
vasculatur
heart
differ
receptor
carey
et
al
voro
et
al
receptor
describ
danser
chapter
volum
human
heart
chymas
initi
discov
homogen
human
heart
propos
major
pathway
convers
ang
ang
ii
heart
urata
et
al
given
chymas
inhibit
ace
inhibitor
repres
potenti
pathway
continu
ang
ii
format
patient
take
ace
inhibitor
therapi
dellitalia
et
al
therebi
provid
rational
possibl
superior
receptor
blocker
arb
therapi
ace
inhibitor
therapi
howev
studi
effect
ace
inhibit
rat
mice
human
ace
gene
knockout
mice
show
ace
domin
pathway
ang
ii
format
heart
campbel
et
al
campbel
et
al
zeitz
et
al
campbel
et
al
acerel
carboxypeptidas
like
ace
membraneassoci
secret
metalloproteas
express
predominantli
endothelium
donoghu
et
al
tipni
et
al
ham
et
al
express
human
tissu
rel
high
level
renal
cardiovascular
tissu
also
gut
harmer
et
al
contrast
dipeptidyl
carboxypeptidas
activ
ace
cleav
ang
ang
also
cleav
ang
ii
ang
inhibit
ace
inhibitor
kinet
consider
make
unlik
contribut
ang
metabol
vivo
jaspard
et
al
vicker
et
al
ace
similar
k
ang
respect
k
cat
ace
approxim
higher
k
cat
k
ratio
approxim
higher
ace
x
lmol
per
x
lmol
per
contrast
k
k
cat
k
cat
k
ratio
x
lmol
per
ang
ii
vicker
et
al
make
like
particip
ang
ii
metabol
initi
genet
studi
suggest
import
role
ang
peptid
metabol
heart
gene
knockout
mous
report
cardiomyopath
phenotyp
associ
increas
ang
ii
level
plasma
heart
kidney
addit
cardiomyopath
phenotyp
amelior
concomit
ace
gene
knockout
suggest
alter
ang
peptid
metabol
contribut
phenotyp
crackow
et
al
subsequ
studi
gene
knockout
mous
normal
cardiac
phenotyp
although
enhanc
pressor
respons
ang
ii
administr
gurley
et
al
activ
report
increas
heart
patient
heart
failur
zisman
et
al
howev
measur
ang
peptid
coronari
venou
blood
patient
heart
failur
ischaem
heart
diseas
support
import
role
either
ang
ang
ii
metabol
human
heart
campbel
et
al
elucid
role
ang
ii
metabol
must
await
develop
specif
inhibitor
effect
ra
heart
vasculatur
system
local
action
ang
ii
impact
heart
system
action
ang
ii
includ
vasoconstrictor
action
increas
blood
pressur
stimul
aldosteron
secret
increas
aldosteron
level
may
produc
hypokalaemia
contribut
cardiac
fibrosi
brilla
et
al
local
cardiac
action
ang
ii
includ
inotrop
hypertroph
effect
cardiac
remodel
paul
et
al
receptor
stimul
induc
myocyt
hypertrophi
collagen
synthesi
regitzzagrosek
et
al
moreov
ang
ii
may
contribut
oxid
stress
inflamm
thrombosi
dzau
duprez
mediat
nadph
oxidas
activ
lead
gener
reactiv
oxygen
speci
wide
implic
vascular
inflamm
fibrosi
li
et
al
mehta
et
al
ang
ii
also
activ
gene
transcript
factor
involv
vascular
inflamm
remodel
oettgen
ang
ii
metabolit
ang
iv
may
promot
thrombosi
stimul
plasminogen
activ
inhibitor
type
product
vasculatur
van
leeuwen
et
al
feener
et
al
kerin
et
al
addit
ang
ii
may
promot
thrombosi
activ
nuclear
factor
bdepend
proinflammatori
gene
acceler
vascular
express
tissu
factor
dieli
et
al
ang
ii
stimul
endothelin
releas
kohno
et
al
moreau
et
al
endothelin
blockad
prevent
cardiovascular
action
ang
ii
webb
et
al
rajagopalan
et
al
herizi
et
al
ang
biolog
activ
peptid
ferrario
et
al
main
pathway
ang
format
cleavag
ang
neutral
endopeptidas
nep
endopeptidas
yamamoto
et
al
duncan
et
al
fig
ang
may
also
form
cleavag
ang
ii
signific
pathway
remain
establish
mani
action
ang
contrari
ang
ii
ang
propos
function
counterregulatori
hormon
blood
pressur
control
cardiovascular
action
ang
ii
ang
reduc
blood
pressur
produc
endotheliumdepend
vasodilat
benter
et
al
et
al
benter
et
al
nakamoto
et
al
brosnihan
et
al
le
tran
et
al
action
may
due
part
potenti
ang
hypotens
effect
kinin
paula
et
al
lima
et
al
andor
stimul
vascular
prostaglandin
product
benter
et
al
paula
et
al
support
role
kininmedi
nitric
oxid
product
vasodil
effect
ang
induc
vasodilat
hypotens
attenu
nitric
oxid
synthas
no
inhibit
et
al
gorelik
et
al
type
bradykinin
b
receptor
antagonist
icatib
et
al
abba
et
al
lima
et
al
gorelik
et
al
also
receptor
antagon
lima
et
al
moreov
ang
stimul
nitric
oxid
releas
coronari
vessel
block
icatib
brosnihan
et
al
high
concentr
ang
inhibit
ace
lead
suggest
ang
potenti
effect
bradykinin
ace
inhibit
li
et
al
howev
ic
ang
inhibit
ace
nmoll
unlik
endogen
ang
level
would
suffici
produc
effect
ang
like
ace
inhibitor
may
potenti
action
b
receptor
agonist
indirect
mechan
independ
bradykinin
hydrolysi
deddish
et
al
possibl
sensitis
b
receptor
marcic
et
al
mechan
potenti
kinininduc
hypotens
ang
unlik
oper
vivo
howev
micromolar
concentr
ang
requir
produc
effect
deddish
et
al
plasma
ang
level
less
ang
ii
level
except
ace
inhibit
ang
level
increas
severalfold
parallel
increas
ang
level
lawrenc
et
al
menard
et
al
tissu
level
ang
low
undetect
even
ace
inhibit
campbel
et
al
therefor
uncertainti
whether
ang
level
suffici
play
role
cardiovascular
physiolog
diseas
state
human
figur
show
outlin
pathway
kinin
peptid
format
proport
kininogen
hydroxyl
pro
bradykinin
sequenc
lead
format
hydroxyl
kinin
peptid
kininogen
sole
precursor
kinin
peptid
code
singl
gene
differenti
splice
initi
mrna
transcript
produc
two
differ
mrna
code
either
high
low
molecular
weight
kininogen
glycoprotein
contain
kinin
sequenc
mid
portion
tissu
kallikrein
plasma
kallikrein
serin
proteas
wherea
singl
gene
code
plasma
kallikrein
larg
famili
tissu
kallikrein
gene
although
tissu
kallikrein
known
gener
kinin
peptid
yousef
et
al
kininogen
tissu
kallikrein
express
mani
differ
tissu
plasma
kallikrein
predominantli
express
liver
although
recent
studi
suggest
express
plasma
kallikrein
brain
takano
et
al
human
plasma
kallikrein
form
bradykinin
high
molecular
weight
kininogen
wherea
tissu
kallikrein
form
kallidin
high
low
molecular
weight
kininogen
fig
contrast
plasma
tissu
kallikrein
gener
outlin
format
kallidin
bradykinin
peptid
human
proport
high
molecular
weight
kininogen
hydroxyl
pro
bradykinin
sequenc
give
rise
hydroxyl
nonhydroxyl
peptid
adapt
campbel
bradykinin
rodent
bhoola
et
al
bradykinin
may
also
gener
aminopeptidasemedi
cleavag
kallidin
altern
pathway
kinin
format
involv
enzym
kallikrein
may
oper
diseas
state
although
low
molecular
weight
kininogen
poor
substrat
plasma
kallikrein
form
bradykinin
presenc
neutrophil
elastas
cleav
fragment
low
molecular
weight
kininogen
render
much
suscept
cleavag
plasma
kallikrein
sato
et
al
moreov
combin
mast
cell
tryptas
neutrophil
elastas
releas
bradykinin
oxid
kininogen
resist
cleavag
kallikrein
kozik
et
al
kinin
product
vivo
control
part
endogen
inhibitor
kallikrein
enzym
main
inhibitor
plasma
kallikrein
inhibitor
macroglobulin
antithrombin
iii
bhoola
et
al
import
inhibitor
tissu
kallikrein
kallistatin
although
function
kallistatin
vivo
uncertain
chao
et
al
compon
function
kk
express
heart
heart
vasculatur
express
tissu
kallikrein
oza
et
al
xiong
et
al
nolli
et
al
nolli
et
al
addit
plasma
kallikrein
member
contact
system
gener
bradykinin
endotheli
surfac
blood
vessel
campbel
dose
relat
effect
ace
inhibitor
perindopril
ang
ii
ang
bradykinin
level
cardiac
ventricl
control
rat
rat
myocardi
infarct
p
compar
mgkg
per
day
perindopril
data
adapt
campbel
et
al
duncan
et
al
kinin
act
via
two
type
kinin
receptor
b
b
receptor
b
receptor
normal
predomin
wherea
b
receptor
induc
tissu
injuri
kk
gener
bioactiv
kinin
peptid
bradykinin
hyp
kallidin
hyp
kallidin
act
b
receptor
wherea
carboxypeptidas
metabolit
desarg
bradykinin
desarg
hyp
bradykinin
desarg
kallidin
desarg
hyp
kallidin
act
b
receptor
hydroxyl
kinin
similar
biolog
activ
nonhydroxyl
kinin
particular
interest
recent
report
human
b
receptor
activ
plasma
tissu
kallikrein
hecquet
et
al
cathepsin
g
trypsin
similarli
activ
b
receptor
activ
block
icatib
thu
b
receptor
may
belong
new
group
serineproteaseactiv
receptor
hecquet
et
al
ace
one
mani
enzym
metabolis
kinin
peptid
campbel
effici
metabol
import
determin
level
blood
tissu
consequ
inhibit
singl
enzym
contribut
kinin
metabol
caus
modest
increas
kinin
level
kinin
peptid
broad
spectrum
activ
system
local
cardiac
action
impact
heart
bhoola
et
al
kinin
peptid
act
mani
differ
second
messeng
system
particular
nitric
oxid
prostaglandin
bhoola
et
al
b
receptor
particip
inhibitori
interact
endotheli
no
eno
revers
bradykinin
ju
et
al
interact
may
recruit
eno
b
receptor
allow
effect
coupl
bradykinin
signal
nitric
oxid
pathway
kinin
potent
vasodil
promot
diuresi
natriuresi
kinin
high
concentr
also
particip
cardin
featur
inflamm
produc
vascular
permeabl
neutrophil
chemotaxi
pain
bhoola
et
al
cardiac
bradykinin
level
increas
acut
phase
myocardi
infarct
rat
duncan
et
al
contrast
found
decreas
kallidin
level
coronari
sinu
blood
subject
heart
failur
suggest
downregul
cardiac
kk
heart
failur
duncan
et
al
larg
bodi
evid
demonstr
antihypertroph
cardioprotect
action
kk
griolcharhbili
et
al
koch
et
al
park
et
al
spillmann
et
al
cardioprotect
effect
bradykinin
includ
reduct
arrhythmia
reduct
lactat
lactat
dehydrogenas
creatin
kinas
releas
increas
myocardi
contractil
myocardi
level
glycogen
adenosin
triphosph
creatin
phosphat
postischaem
reperfus
isol
work
rat
heart
linz
et
al
moreov
bradykinin
suppress
endothelin
releas
postischaem
rat
heart
brunner
et
al
kinin
protect
ischaemiareperfus
injuri
decreas
endotheli
adher
leukocyt
lead
attenu
postischaem
leukocyt
adher
attenu
disrupt
microvascular
barrier
reduc
tissu
injuri
shigematsu
et
al
mani
action
kinin
counteract
ang
ii
caus
endotheliumdepend
vasodilat
endotheli
releas
nitric
oxid
prostacyclin
pelc
et
al
lamontagn
et
al
gallagh
et
al
kinin
also
counteract
hypertroph
action
ang
ii
reduc
collagen
format
gallagh
et
al
ritchi
et
al
administr
kinin
receptor
antagonist
indic
role
endogen
kinin
regul
coronari
vasculatur
myocardi
respons
myocardi
infarct
icatib
reduc
flowdepend
vasodilat
human
coronari
arteri
indic
role
kinin
regul
coronari
vasculatur
grove
et
al
icatib
enhanc
myocardi
interstiti
deposit
collagen
follow
myocardi
infarct
rat
indic
role
endogen
kinin
modul
collagen
deposit
howev
icatib
modifi
morpholog
molecular
marker
cardiomyocyt
hypertrophi
wollert
et
al
kinin
particip
process
ischaem
precondit
also
shown
limit
reperfus
injuri
baxter
et
al
kinin
may
also
protect
thrombosi
stimul
endotheli
releas
nitric
oxid
prostacyclin
tissu
plasminogen
activ
dieli
et
al
new
properti
kinin
peptid
discov
exampl
b
receptor
may
import
role
angiogenesi
emanu
et
al
acsdkp
inhibitor
pluripot
haemopoiet
stem
cell
prolifer
lenfant
et
al
bonnet
et
al
normal
present
human
plasma
mononuclear
cell
pradel
et
al
acsdkp
releas
precursor
prolyl
oligopeptidas
cavasin
et
al
cleav
inact
form
dipeptidyl
carboxypeptidas
activ
ntermin
catalyt
domain
ace
rousseau
et
al
acsdkp
min
halflif
circul
probabl
releas
continu
import
ace
acsdkp
metabol
shown
increas
acsdkp
plasma
level
accompani
ace
inhibit
acsdkp
inhibit
dna
collagen
synthesi
cardiac
fibroblast
rhaleb
et
al
prevent
revers
myocardi
inflamm
fibrosi
rat
heart
failur
myocardi
infarct
acsdkp
stimul
coronari
vasculogenesi
angiogenesi
wang
et
al
smart
et
al
acsdkp
increas
myocardi
capillari
densiti
rat
myocardi
infarct
wang
et
al
mani
clinic
trial
demonstr
therapeut
benefit
ace
inhibit
heart
failur
ischaem
heart
diseas
note
howev
effect
ace
inhibitor
dose
relat
larg
clinic
trial
necess
use
one
dose
drug
result
trial
much
measur
effect
dose
measur
effect
drug
use
less
optim
dose
may
fail
reveal
drug
true
therapeut
potenti
particular
concern
headtohead
comparison
two
activ
drug
result
may
due
choic
dose
choic
drug
clinician
strive
achiev
drug
dose
proven
benefit
clinic
trial
present
larg
proport
patient
receiv
ace
inhibitor
therapi
receiv
less
optim
dose
lenzen
et
al
measur
plasma
ang
peptid
level
feasibl
monitor
ace
inhibitor
therapi
measur
plasma
acsdkp
level
may
assist
regard
struther
et
al
heart
failur
associ
neurohormon
activ
includ
increas
renin
ang
ii
aldosteron
level
activ
sympathet
nervou
system
franci
et
al
increas
ang
ii
aldosteron
noradrenalin
adrenalin
level
predict
increas
mortal
heart
failur
patient
swedberg
et
al
therapi
counteract
effect
ra
sympathet
nervou
system
activ
cornerston
heart
failur
therapi
hunt
et
al
swedberg
et
al
acut
ace
inhibit
heart
failur
patient
promot
arterioand
venodilat
reduct
afterload
preload
associ
increas
cardiac
output
stroke
volum
stroke
work
index
along
decreas
pulmonari
capillari
wedg
pressur
indic
improv
left
ventricular
lv
function
gavra
et
al
ader
et
al
cooper
north
scandinavian
enalapril
surviv
studi
consensu
demonstr
reduc
mortal
improv
symptom
enalapril
therapi
patient
sever
heart
failur
consensu
trial
studi
group
moreov
mortal
lower
enalapril
therapi
hydralazineisosorbid
dinitr
therapi
second
veteran
administr
cooper
vasodilatorheart
failur
trial
vheft
ii
cohn
et
al
studi
left
ventricular
dysfunct
solvd
confirm
surviv
benefit
enalapril
therapi
patient
reduc
lv
eject
fraction
heat
failur
solvd
investig
also
demonstr
prevent
heart
failur
asymptomat
subject
reduc
lv
eject
fraction
solvd
investig
ace
inhibit
improv
surviv
symptom
function
capac
reduc
hospitalis
patient
moder
sever
heart
failur
lv
systol
dysfunct
flather
et
al
abdulla
et
al
ace
inhibit
recommend
firstlin
therapi
patient
reduc
lv
eject
fraction
without
symptom
uptitr
dose
shown
effect
clinic
trial
hunt
et
al
swedberg
et
al
although
patient
recruit
consensu
vheft
ii
sovd
studi
reduc
lv
eject
fraction
due
often
ischaem
heart
diseas
enrol
sever
month
myocardi
infarct
studi
rat
demonstr
surviv
advantag
ace
inhibitor
therapi
commenc
day
myocardi
infarct
pfeffer
et
al
addit
ace
inhibit
reduc
arteri
pressur
total
peripher
resist
attenu
lv
remodel
prevent
deterior
cardiac
output
stroke
volum
index
prevent
increas
lv
volum
lv
chamber
stiff
lv
end
diastol
pressur
rat
myocardi
infarct
pfeffer
et
al
benefit
ace
inhibit
rat
myocardi
infarct
confirm
patient
surviv
ventricular
enlarg
save
trial
show
reduc
mortal
ace
inhibitor
therapi
commenc
day
myocardi
infarct
patient
asymptomat
lv
dysfunct
pfeffer
et
al
addit
ace
inhibitor
therapi
reduc
incid
fatal
nonfat
major
cardiovascular
event
includ
develop
sever
heart
failur
recurr
myocardi
infarct
benefit
ace
inhibitor
therapi
myocardi
infarct
confirm
acut
infarct
ramipril
efficaci
air
trandolapril
cardiac
evalu
trace
studi
acut
infarct
ramipril
efficaci
air
studi
investig
kober
et
al
air
studi
recruit
patient
day
myocardi
infarct
shown
clinic
evid
heart
failur
time
trace
studi
recruit
patient
day
myocardi
infarct
lv
eject
fraction
air
trace
studi
show
surviv
advantag
ace
inhibitor
therapi
trace
studi
show
less
develop
sever
heart
failur
larg
clinic
trail
confirm
benefit
ace
inhibit
myocardi
infarct
gruppo
collabor
group
addit
mortal
benefit
reduct
sever
heart
failur
ace
inhibit
myocardi
infarct
attenu
lv
remodel
lv
enlarg
increas
lv
mass
improv
lv
eject
fraction
myocardi
infarct
pfeffer
et
al
sharp
et
al
sogaard
et
al
johnson
et
al
contrast
consensu
ii
trial
found
commenc
ace
inhibitor
therapi
within
hour
myocardi
infarct
improv
surviv
swedberg
et
al
failur
ace
inhibit
improv
outcom
consensu
ii
trial
may
due
protocol
ace
inhibitor
treatment
start
intraven
infus
mg
enalaprilat
within
hour
onset
chest
pain
follow
administr
oral
enalapril
intravascular
administr
ace
inhibitor
neg
inotrop
effect
sever
human
studi
foult
et
al
haber
et
al
zeitz
et
al
although
anoth
friedrich
et
al
thu
failur
ace
inhibitor
therapi
produc
benefit
consensu
ii
trial
may
due
neg
inotrop
effect
intraven
administ
enalaprilat
addit
administr
within
hour
chest
pain
current
european
societi
cardiolog
guidelin
recommend
initi
ace
inhibitor
acut
phase
myocardi
infarct
patient
sign
symptom
heart
failur
even
transient
improv
surviv
reduc
reinfarct
hospitalis
heart
failur
hope
studi
base
emerg
evid
ace
inhibit
reduc
risk
myocardi
infarct
patient
low
eject
fraction
pfeffer
et
al
yusuf
et
al
lonn
et
al
examin
effect
addit
mg
ramipril
standard
therapi
patient
age
least
year
histori
coronari
arteri
diseas
stroke
peripher
vascular
diseas
diabet
plu
least
one
cardiovascular
risk
factor
hypertens
elev
total
cholesterol
level
low
highdens
lipoprotein
cholesterol
level
cigarett
smoke
microalbuminuria
patient
exclud
heart
failur
known
low
eject
fraction
take
ace
inhibitor
vitamin
e
uncontrol
hypertens
overt
nephropathi
myocardi
infarct
stroke
within
week
studi
began
mean
followup
year
ramipril
reduc
primari
outcom
composit
myocardi
infarct
stroke
death
cardiovascular
caus
rel
risk
confid
interv
p
treatment
ramipril
reduc
rate
death
cardiovascular
caus
allcaus
mortal
myocardi
infarct
revascularis
procedur
cardiac
arrest
heart
failur
complic
relat
diabet
europa
studi
examin
effect
addit
mg
perindopril
standard
therapi
patient
previou
myocardi
infarct
angiograph
evid
coronari
heart
diseas
coronari
revascular
posit
stress
test
past
histori
heart
failur
record
subject
none
clinic
sign
heart
failur
new
york
heart
associ
class
none
class
ii
higher
mean
followup
year
perindopril
reduc
primari
outcom
composit
cardiovascular
death
nonfat
myocardi
infarct
cardiac
arrest
success
resuscit
rel
risk
confid
interv
p
main
contributor
reduct
primari
outcom
reduct
nonfat
myocardi
infarct
perindopril
also
reduc
incid
heart
failur
requir
hospitalis
contrast
prevent
event
angiotensin
convert
enzym
inhibit
peac
studi
fail
show
effect
ace
inhibit
primari
endpoint
peac
trial
investig
peac
studi
examin
effect
addit
mg
trandolapril
standard
therapi
cardiovascular
event
patient
stabl
coronari
heart
diseas
preserv
lv
function
median
followup
year
trandolapril
produc
nonstatist
signific
reduct
primari
endpoint
composit
cardiovascular
death
myocardi
infarct
coronari
revascular
cardiovascular
death
nonfat
myocardi
infarct
although
trandolapril
reduc
hospitalis
death
due
heart
failur
particip
peac
studi
lower
risk
cardiovascular
event
hope
europa
studi
baselin
blood
pressur
peac
particip
less
patient
hope
europa
studi
similar
level
achiev
activ
therapi
hope
europa
studi
addit
peac
particip
receiv
intens
manag
risk
factor
hope
europa
studi
peac
particip
receiv
lipid
lower
therapi
hope
europa
undergon
coronari
revascular
enrol
hope
europa
thu
peac
particip
event
rate
similar
gener
popul
annualis
rate
death
aggress
manag
risk
factor
may
negat
potenti
benefit
ace
inhibitor
therapi
debat
reason
failur
peac
studi
show
effect
trandolapril
primari
endpoint
pitt
fox
et
al
although
dose
type
ace
inhibitor
may
implic
like
explan
low
event
rate
rel
low
risk
popul
necessit
inclus
revascularis
part
primari
endpoint
studi
suffici
statist
power
achiev
aim
ischemia
manag
accupril
post
bypass
graft
via
inhibit
angiotensin
convert
enzym
imagin
studi
similarli
show
lack
benefit
mg
quinapril
optim
treat
lowrisk
patient
coronari
arteri
bypass
graft
keuper
et
al
pool
analysi
hope
europa
peac
trial
show
ace
inhibit
reduc
caus
cardiovascular
mortal
nonfat
myocardi
infarct
stroke
heart
failur
coronari
arteri
bypass
surgeri
lead
recommend
ace
inhibitor
consid
patient
atherosclerosi
dagenai
et
al
metaanalysi
hope
europa
peac
studi
came
similar
conclus
almallah
et
al
howev
number
need
treat
year
prevent
either
one
death
one
nonfat
myocardi
infarct
one
coronari
revascularis
procedur
almallah
et
al
current
european
societi
cardiolog
guidelin
state
ace
inhibit
well
establish
treatment
heart
failur
lv
dysfunct
treatment
diabet
patient
thu
appropri
consid
ace
inhibitor
treatment
patient
stabl
angina
pectori
coexist
hypertens
diabet
heart
failur
asymptomat
lv
dysfunct
postmyocardi
infarct
angina
patient
without
coexist
indic
ace
inhibitor
treatment
anticip
benefit
treatment
possibl
absolut
risk
reduct
weigh
cost
risk
sideeffect
dose
agent
use
proven
efficaci
indic
fox
et
al
et
al
system
effect
includ
reduct
circul
ang
ii
aldosteron
level
increas
kinin
acsdkp
level
decreas
ang
ii
increas
kinin
level
contribut
reduct
blood
pressur
ace
inhibit
ongo
debat
extent
benefit
ace
inhibit
relat
blood
reduct
oppos
intrins
benefit
ace
inhibit
sever
et
al
major
contributor
benefit
ace
inhibit
heart
failur
ischaem
heart
diseas
may
reduct
system
blood
pressur
consequ
reduct
heart
work
ace
inhibit
may
improv
cardiac
function
reduc
coronari
vascular
resist
patient
heart
failur
therebi
augment
cardiac
blood
flow
dietz
et
al
ace
inhibit
reduc
circul
tissu
level
ang
ii
anim
human
campbel
et
al
duncan
et
al
campbel
et
al
zeitz
et
al
ace
inhibit
produc
modest
reduct
ang
ii
level
europa
particip
ceconi
et
al
howev
effect
ace
inhibit
ang
ii
level
variabl
depend
respons
renin
secret
situat
renin
show
littl
increas
respons
ace
inhibit
level
ang
ii
metabolit
show
mark
fall
littl
chang
level
ang
metabolit
contrast
larg
increas
renin
level
respons
ace
inhibit
also
increas
level
ang
metabolit
increas
ang
level
promot
ang
ii
format
residu
uninhibit
ace
serin
proteas
pathway
ang
convers
therebi
buffer
fall
ang
ii
level
ace
inhibit
improv
surviv
heart
failur
patient
ace
inhibitor
therapi
associ
reduct
ang
ii
aldosteron
level
swedberg
et
al
role
renin
determin
respons
ang
ii
level
ace
inhibit
evid
heart
failur
mani
patient
continu
elev
ang
ii
level
despit
ace
inhibitor
therapi
roig
et
al
campbel
et
al
note
maxim
recommend
dose
ace
inhibitor
complet
prevent
ace
mediat
format
ang
ii
heart
failur
jord
et
al
benefici
therapeut
effect
concomit
therapi
heart
failur
may
due
part
associ
reduct
renin
ang
ii
level
campbel
et
al
effect
ace
inhibitor
ang
ii
level
dose
depend
fig
studi
rat
show
tissuespecif
differ
doserel
effect
ace
inhibit
ang
ii
level
campbel
renal
ang
ii
level
reduc
lower
dose
ace
inhibitor
requir
reduc
ang
ii
level
tissu
heart
fig
ang
due
part
increas
ang
level
subsequ
convers
ang
anoth
mechan
increas
ang
level
ace
inhibit
inhibit
ang
metabol
given
ace
import
pathway
ang
metabol
yamada
et
al
studi
rat
led
propos
increas
ang
level
mediat
part
hypotens
effect
ace
inhibit
iyer
et
al
iyer
et
al
howev
yet
evid
mechan
oper
patient
receiv
ace
inhibitor
therapi
ampl
evid
kinin
peptid
contribut
therapeut
effect
ace
inhibitor
linz
et
al
ace
inhibitor
increas
circul
tissu
level
bradykinin
anim
fig
human
campbel
et
al
duncan
et
al
zeitz
et
al
effect
ace
inhibit
kinin
peptid
level
tissu
compart
depend
contribut
ace
rel
kininas
kinin
peptid
metabol
compart
ace
inhibitor
therapi
increas
either
bradykinin
kallidin
peptid
level
cardiac
atria
patient
ischaem
heart
diseas
despit
reduct
ang
ii
level
mainten
low
level
kinin
peptid
effici
metabol
relev
success
ace
inhibitor
therapi
ace
inhibit
modest
effect
kinin
peptid
level
mani
kininas
contribut
kinin
metabol
reason
ace
inhibitor
gener
free
side
effect
angioneurot
oedema
one
might
expect
increas
kinin
peptid
level
nussberg
et
al
nussberg
et
al
studi
kinin
receptor
antagonist
indic
role
kinin
cardiovascular
action
ace
inhibitor
anim
human
linz
et
al
studi
human
indic
role
b
receptor
flowdepend
vasodilat
normal
volunt
hornig
et
al
hypotens
effect
patient
hypertens
gainer
et
al
squir
et
al
role
b
receptor
indic
system
haemodynam
effect
ace
inhibit
patient
heart
failur
witherow
et
al
cruden
et
al
cardioprotect
effect
ace
inhibit
attenu
icatib
includ
reduct
arrhythmia
reduct
lactat
lactat
dehydrogenas
creatin
kinas
releas
increas
myocardi
contractil
myocardi
level
glycogen
adenosin
triphosph
creatin
phosphat
reperfus
ischaem
isol
work
rat
heart
linz
et
al
icatib
attenu
ace
inhibitorinduc
increas
coronari
flow
nitric
oxid
level
dog
myocardi
ischaemia
kitakaz
et
al
icatib
also
prevent
potenti
ischaem
precondit
ace
inhibit
human
atria
morri
et
al
postischaem
antiarrhythm
effect
ace
inhibit
may
mediat
kinininduc
suppress
endothelin
releas
brunner
et
al
icatib
prevent
reduct
myocardi
infarct
size
reduct
postinfarct
remodel
ace
inhibit
anim
model
linz
et
al
hartman
et
al
stauss
et
al
mcdonald
et
al
hu
et
al
howev
subsequ
studi
vivo
canin
model
myocardi
ischaem
injuri
show
effect
ace
inhibit
infarct
size
black
et
al
moreov
icatib
modifi
antihypertroph
effect
ace
inhibit
rat
myocardi
infarct
although
partial
revers
reduct
myocardi
collagen
deposit
ace
inhibitor
therapi
one
studi
wollert
et
al
possibl
mechan
kinin
peptid
mediat
therapeut
benefit
ace
inhibit
includ
promot
endotheli
product
nitric
oxid
prostacylin
therebi
contribut
correct
endotheli
dysfunct
reduc
oxid
stress
linz
et
al
et
al
ace
inhibit
induc
endotheli
no
eno
vasculatur
control
rat
attenu
induct
induc
no
ino
rat
administ
bacteri
lipopolysaccharid
bachetti
et
al
icatib
prevent
increas
nitric
oxid
format
heart
reduct
myocardi
oxygen
consumpt
accompani
ace
inhibit
dog
zhang
et
al
icatib
also
prevent
antiprolif
effect
ace
inhibit
neointima
format
follow
endotheli
injuri
rat
carotid
arteri
linz
et
al
increas
capillari
densiti
induc
chronic
ace
inhibitor
treatment
strokepron
spontan
hypertens
rat
gohlk
et
al
part
benefit
ace
inhibit
may
due
enhanc
insulinmedi
muscl
glucos
uptak
also
attenu
icatib
henriksen
et
al
henriksen
et
al
ace
inhibit
also
affect
kk
mechan
separ
prevent
kinin
degrad
exampl
chronic
ace
inhibit
mice
rat
induc
renal
vascular
b
receptor
express
without
modif
b
receptor
express
marincastano
et
al
moreov
enalaprilat
ace
inhibitor
nanomolar
concentr
shown
directli
activ
human
b
receptor
absenc
ace
b
receptor
ligand
ignjatov
et
al
sever
studi
show
ace
inhibitor
may
potenti
effect
bradykinin
mechan
independ
prevent
kinin
metabol
involv
direct
interact
ace
b
receptor
fleme
attenu
sequestr
b
receptor
benz
et
al
chen
et
al
addit
membran
ace
appear
signal
cascad
activ
bind
ace
inhibitor
fleme
one
approach
differenti
respect
role
ra
kk
mediat
therapeut
benefit
ace
inhibit
comparison
ace
arb
therapi
comparison
ace
inhibitor
arb
therapi
myocardi
infarct
patient
heart
failur
show
differ
outcom
pitt
et
al
dickstein
et
al
pfeffer
et
al
mcmurray
et
al
studi
suggest
ace
inhibitor
arb
therapi
act
blockad
ra
role
bradykinin
exclud
losartan
shown
increas
bradykinin
level
hypertens
human
campbel
et
al
maxim
recommend
dose
ace
inhibitor
complet
prevent
ace
mediat
format
ang
ii
heart
failur
jord
et
al
combin
ace
inhibitor
arb
therapi
produc
complet
blockad
ra
depend
dose
regimen
individu
therapi
menard
et
al
azizi
et
al
combin
therapi
improv
outcom
heart
failur
patient
cohn
et
al
mcmurray
et
al
follow
myocardi
infarct
mcmurray
et
al
ace
inhibit
caus
severalfold
increas
acsdkp
level
may
contribut
decreas
cardiac
inflamm
fibrosi
increas
myocardi
capillari
densiti
myocardi
infarct
wang
et
al
yang
et
al
elev
acsdkp
level
ace
inhibitor
therapi
may
also
contribut
anaemia
experienc
heart
failur
patient
receiv
ace
inhibitor
therapi
van
der
meer
et
al
heart
failur
patient
increas
plasma
aldosteron
level
consequ
stimul
aldosteron
secret
increas
ang
ii
level
weber
evid
reduc
aldosteron
level
may
contribut
therapeut
benefit
ace
inhibit
reduc
hypokalaemia
patient
receiv
ramipril
therapi
hope
studi
mann
et
al
addit
promot
sodium
retent
oedema
format
aldosteron
may
promot
cardiac
fibrosi
deterior
cardiac
function
brilla
et
al
possibl
clinic
import
mechan
shown
benefit
aldosteron
receptor
antagonist
patient
heart
failur
patient
lv
dysfunct
myocardi
infarct
pitt
et
al
pitt
et
al
mani
author
suggest
reduct
sympathet
activ
may
accompani
ace
inhibit
due
reduct
stimul
sympathet
activ
ang
ii
howev
although
ace
inhibitor
therapi
lead
reduct
sympathet
nervou
system
activ
heart
failur
thought
mainli
secondari
improv
cardiovascular
haemodynam
rather
specif
consequ
reduc
stimul
sympathet
nervou
system
ang
ii
esler
et
al
cardiac
hypertrophi
well
recognis
risk
factor
death
cardiovascular
event
levi
et
al
ace
inhibitor
reduc
cardiac
hypertrophi
hypertens
patient
dahlof
et
al
also
reduc
progress
lv
remodel
myocardi
infarct
ferrari
ventricular
remodel
domin
role
pathogenesi
heart
failur
prevent
remodel
consid
import
mechan
benefit
ace
inhibitor
therapi
heart
failur
myocardi
infarct
cohn
abdulla
et
al
reduct
myocardi
infarct
ischaem
event
ace
inhibit
rais
possibl
drug
inhibit
atherosclerosi
ace
inhibitor
correct
endotheli
dysfunct
patient
heart
failur
ischaem
heart
diseas
mancini
et
al
ceconi
et
al
effect
ace
inhibit
may
due
reduct
oxid
stress
vascular
remodel
inflamm
reduc
ang
ii
level
increas
kinin
level
howev
current
evid
allow
data
extrapol
reduct
atherogenesi
ace
inhibit
human
despit
prevent
atherosclerosi
anim
model
ace
inhibitor
therapi
abl
reduc
atherogenesi
patient
ace
inhibit
cilazapril
prevent
restenosi
angioplasti
mercat
mercat
studi
group
faxon
similarli
quinapril
reduc
restenosi
coronari
stent
fact
late
loss
minimum
lumen
diamet
significantli
higher
quinapril
group
control
meuric
et
al
addit
ace
inhibit
enalapril
fail
reduc
progress
coronari
atherosclerosi
assess
intravascular
ultrasound
patient
coronari
arteri
diseas
nissen
et
al
metaanalysi
randomis
control
studi
effect
antihypertens
therapi
progress
carotid
intimamedia
thick
show
weak
nonsignific
reduct
progress
carotid
intimamedia
thick
ace
inhibitor
therapi
signific
heterogen
studi
wang
et
al
studi
show
reduct
progress
intimamedia
thick
ace
inhibit
note
calcium
channel
blocker
significantli
effect
ace
inhibitor
reduct
progress
intimamedia
thick
wang
et
al
reduc
rate
myocardi
infarct
ace
inhibitor
therapi
may
also
due
effect
therapi
mechan
thrombosi
fibrinolysi
ace
inhibit
reduc
plasma
level
antigen
activ
normal
subject
low
salt
diet
subject
follow
myocardi
infarct
wright
et
al
moriyama
et
al
oshima
et
al
vaughan
et
al
brown
et
al
brown
et
al
although
effect
ace
inhibit
confirm
studi
patient
previou
myocardi
infarct
zehetgrub
et
al
pedersen
et
al
ace
inhibit
also
reduc
antigen
activ
subject
congest
cardiac
failur
goodfield
et
al
diabet
well
recognis
acceler
process
cardiovascular
diseas
reduct
diabet
incid
may
contribut
therapeut
benefit
ace
inhibit
mani
larg
clinic
trial
includ
hope
peac
solvd
studi
show
reduc
incid
type
diabet
ace
inhibitor
therapi
abuissa
et
al
howev
diabet
reduct
assess
ramipril
rosiglitazon
medic
dream
studi
found
ramipril
reduc
diabet
incid
among
person
impair
fast
glucos
level
impair
glucos
toler
although
significantli
increas
regress
normoglycaemia
dream
trial
investig
improv
insulin
resist
may
due
part
enhanc
insulinmedi
muscl
glucos
uptak
ace
inhibit
henriksen
et
al
henriksen
et
al
aortic
complianc
import
determin
coronari
blood
flow
orourk
et
al
recent
metaanalysi
show
ace
inhibitor
decreas
arteri
stiff
mallareddi
et
al
ace
inhibitor
increas
aortic
complianc
may
reduc
central
systol
blood
pressur
maintain
diastol
blood
pressur
therebi
reduc
heart
work
without
compromis
myocardi
perfus
decreas
arteri
stiff
ace
inhibit
may
due
reduc
collagen
deposit
suggest
studi
spontan
hypertens
rat
beneto
et
al
reduct
aortic
collagen
deposit
ace
inhibit
affect
icatib
suggest
effect
ace
inhibit
mediat
kinin
beneto
et
al
atrial
fibril
import
contributor
poor
prognosi
heart
failur
wang
et
al
prevent
atrial
fibril
ace
inhibit
may
contribut
therapeut
benefit
therapi
verm
et
al
given
kinin
peptid
mediat
part
therapeut
benefit
ace
inhibit
action
kinin
mediat
prostaglandin
question
aris
whether
drug
inhibit
prostaglandin
synthesi
may
attenu
effect
ace
inhibit
question
address
systemat
review
interact
aspirin
ace
inhibitor
therapi
teo
et
al
solvd
studi
found
aspirin
prevent
reduct
death
ace
inhibit
interact
aspirin
ace
inhibitor
therapi
signific
trial
examin
howev
solvd
trial
show
aspirin
attenu
prevent
myocardi
infarct
reinfarct
ace
inhibit
contrast
evid
aspirin
attenu
prevent
stroke
hospit
admiss
heart
failur
revascularis
ace
inhibitor
therapi
composit
major
vascular
event
includ
death
myocardi
infarct
reinfarct
hospit
admiss
heart
failur
stroke
revascularis
examin
aspirin
significantli
attenu
benefit
ace
inhibitor
therapi
analysi
show
therefor
aspirin
interact
ace
inhibitor
therapi
least
case
myocardi
infarct
howev
absenc
clear
contraind
concomit
use
aspirin
ace
inhibitor
consid
patient
high
risk
major
vascular
event
teo
et
al
ace
inhibitor
major
role
treatment
prevent
heart
failur
ischaem
heart
diseas
reduct
ang
ii
level
increas
kinin
acsdkp
level
implic
mechan
therapeut
effect
ace
inhibitor
much
detail
mechan
howev
remain
discov
azizi
menard
j
combin
blockad
reninangiotensin
system
angiotensinconvert
enzym
inhibitor
angiotensin
ii
type
receptor
antagonist
circul
bachetti
comini
l
pasini
e
cargnoni
curello
ferrari
r
ace
esler
kay
angiotensin
ii
ace
inhibitor
patient
heart
failur
lancet
swedberg
k
held
p
kjekshu
j
rasmussen
k
l
wedel
h
effect
earli
administr
enalapril
mortal
patient
acut
myocardi
infarctionresult
cooper
new
scandinavian
enalapril
surviv
studi
ii
consensu
ii
n
engl
j
med
takano
hori
narahara
miyak
okamoto
h
express
kininogen
mrna
plasma
kallikrein
mrna
cultur
neuron
astrocyt
mening
cell
rat
brain
immunopharmacolog
teo
kk
yusuf
pfeffer
torppedersen
c
kober
l
hall
pogu
j
latini
r
collin
r
effect
longterm
treatment
angiotensinconvertingenzym
inhibitor
presenc
absenc
aspirin
systemat
review
lancet
acut
infarct
ramipril
efficaci
air
studi
investig
effect
ramipril
mortal
morbid
survivor
acut
myocardi
infarct
clinic
evid
heart
failur
